The expression of CMTM6 and PD-L1 in CRC patients treated with immunotherapy was detected by IF, and the positive expression rates of CMTM6 and PD-L1 were 59.4% (19/32) and 53.1% (17/32), respectively; however, the coexpression rate of CMTM6 and PD-L1 was 31.3% (10/32). This evidence concerns the gene CMTM6 and colorectal carcinoma.